Tardive dyskinesia and withdrawal emergent syndrome in children.
Tardive dyskinesia (TD) is a well-recognized and sometimes permanent adverse effect of treatment with dopamine receptor-blocking drugs (DRBDs), also referred to as neuroleptics. This iatrogenic disorder has been well characterized in adults, but not extensively studied in children. Withdrawal emergent syndrome (WES) is another pediatric movement disorder related to the use of DRBDs. TD and WES are among the most feared adverse effects of DRBD treatment, and have important medical and legal implications. We review published studies of children under the age of 18 years who were exposed to DRBD to determine the clinical spectrum and estimate the possible prevalence of TD and WES. We particularly wish to draw attention to the phenomenology, clinical course and treatment of these childhood-onset disorders. Although avoiding DRBDs is the best strategy for minimizing the risk of TD and WES, physicians who evaluate children exposed to DRBDs must be vigilant and recognize the early symptoms and signs of these syndromes to provide appropriate clinical management.
Harvard Medical School and Massachusetts General Hospital, Boston, MA, USA.
Nicte I
NI
Mejia
Joseph
J
Jankovic
D000293:Adolescent; D014150:Antipsychotic Agents / Q000009:adverse effects; D002648:Child; D002675:Child, Preschool; D018492:Dopamine Antagonists / Q000009:adverse effects*; D004409:Dyskinesia, Drug-Induced / Q000453:epidemiology*; D006801:Humans; D001523:Mental Disorders / Q000188:drug therapy*; D015995:Prevalence
D014150:Antipsychotic Agents; D018492:Dopamine Antagonists